Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Psoriasis - Identifying and Commercializing First-in-Class Innovation


Published on

Market Research Reports, Inc. has announced the addition of “Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation” research report to their offering. See more at-

Published in: Healthcare
  • Be the first to comment

  • Be the first to like this

Psoriasis - Identifying and Commercializing First-in-Class Innovation

  1. 1. Category : Pharma & Healthcare All logos and Images mentioned on this slide belong to their respective owners.
  2. 2. Introduction to Report  Launch Date: June 30, 2014  Number of Pages: 77  Geography Coverage: Global  Available Format: PDF Price For Single User License: USD 3,500 Price For Site User License: USD 7,000 Price For Global User License: USD 10,500 Delivery Time: Within 24 Hours (During Working Days)
  3. 3. About the Report “Frontier Pharma: Psoriasis Identifying and Commercializing First-in-Class Innovation”, which identifies and assesses first-in-class innovation in the psoriasis development pipeline. Despite mostly targeting established molecules, the psoriasis pipeline is showing a high level of innovation in first-in-class molecules, including novel angiogenic drugs, growth factors, chaperone proteins and cytokines, according to Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation report.
  4. 4. Research Findings This report states that first-in-class programs constitute an estimated 27% of the entire psoriasis pipeline, and are predominantly composed of targeted therapies, including cytokine and receptor modulators, nuclear receptor modulators and intracellular kinase inhibitors. There are several novel therapies targeting first-in-class T cell antigens, thanks to a growing understanding of the signaling pathways underlying the psoriasis pathophysiology, in which T cells have been shown to play a substantial role in disease progression. Therapies that can selectively modulate specific subsets of immune cells, without compromising the entire immune system, have become increasingly desirable, according to Publisher.
  5. 5. Research Findings Continues… One such program is Tregalizumab, a humanized Cluster of Differentiation (CD) 4-specific monoclonal antibody. In contrast to other anti-CD4 antibodies, Tregalizumab is able to activate the suppressive properties of regulatory T cells. It is currently in Phase II clinical trials for the treatment of rheumatoid arthritis and in Preclinical development for treating psoriasis. Publisher states that although no preclinical or clinical efficacy data has been disclosed for the antibody, it has been involved in a lucrative co-development deal worth $480 million between Biotest and Abbott Laboratories.
  6. 6. Scope A brief introduction to psoriasis, including symptoms, pathophysiology, and overview of pharmacotherapy The changing molecular target landscape between market and pipeline and particular focal points of innovation Overview of how innovative products are contributing to the pipeline and market for psoriasis Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of phase distribution, molecule type, molecular target, and administration route Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets
  7. 7. Reasons To Buy Understanding of the focal shifts in molecular targets in the psoriasis pipeline Understanding of the distribution of pipeline programs by phase of development, molecule type and molecular target Scientific and clinical analysis of first-in-class developmental programs Assessment of the valuations of licensed and co- developed psoriasis treatments A list of the first-in-class therapies potentially open to deal-making opportunities. Analysis of financial valuations on licensed or co- developed first-in-class therapies and generics
  8. 8. Report Coverage 1. The Case for Innovation 2. Clinical and Commercial Landscape 3. Assessment of Psoriasis Pipeline and Innovation 4. First-in-Class Target and Pipeline Program Evaluation 5. Deals and Strategic Consolidations 6. Appendix For more details regarding Report coverage see the last slide All logos and Images mentioned on this slide belong to their respective owners.
  9. 9. Custom Research:  Are you an industry professional, entrepreneur, venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research. For Any Customization Related query Visit IdeaCenter @
  10. 10. How To Buy This Report? Visit following URL to see Table of Content and purchase this publication: About Market Research Reports, Inc. Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”. Contact : Amitava Sen Email : Phone: +1 302-703-7787 (USA) +91-8762746600 (India)